Health & Fitness
Wed, January 25, 2012
MINNEAPOLIS--([ BUSINESS WIRE ])--Urologix, Inc. (Nasdaq:ULGX) will host a conference call to present fiscal year 2012 second quarter results on Tuesday, January 24, 2012 at 4:00 p.m. CT, following the Companyas post-market press release on the same day. On the day of the call, please dial 1-866-510-0711 and enter the Participant Passcode 86583253 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at [ www.urologix.com ]. Stryker Warren, Jr., Chief Executive Officer, will host the call.
Webcast listeners should log on at least 10 minutes prior to the scheduled start time of the call to register and download or install any required audio software. A replay of the call will be available until January 31, 2012 at 4:00 p.m. CT (5:00 p.m. ET). To listen to the replay, please dial 1-888-286-8010 and enter the Participant Passcode 48088029.
The webcast is also being distributed over CCBNas Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBNas individual investor center at [ www.companyboardroom.com ] or by visiting any of the investor sites in CCBNas Individual Investor Network. Institutional investors can access the call via CCBNas password-protected event management site, StreetEvents ([ www.streetevents.com ]).
About Urologix
Urologix, Inc., based in Minneapolis, develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologixa Cooled ThermoTherapya" produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Cooled ThermoTherapya" product line includes the CoolWave and Targis Control Units and the CTC Advance and Targis catheter families. The Prostiva RF Therapy System distributed by Urologix delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. Both of these products provide safe, effective and lasting relief of the symptoms and obstruction due to BPH. Prostiva is a registered trademark of Medtronic, Inc., used under license. All other trademarks are the property of Urologix.
